Literature DB >> 20573650

Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones.

Marc Riquet1, Alex Arame, Christophe Foucault, Françoise Le Pimpec Barthes.   

Abstract

The lymphatic drainage of solid organ tumors crosses through the lymph nodes (LNs) whose tumoral involvement may still be considered as local disease. Concerning lung cancer, LN involvement may be intrapulmonary (N1), and mediastinal and/or extra-thoracic. More than 30 years ago, mediastinal involved LNs were all considered as N2, and outside the scope of surgery. In 1978, Naruke presented an original article entitled 'Lymph node mapping and curability at various levels of metastasis in resected lung cancer', demonstrating that N2 was not a contraindication to surgery in all patients. The map permitted to localize the favorable N2 on the lung cancer ipsilateral side of the mediastinum. Several maps ensued aiming to discriminate between right and left involvement (1983), and to distinguish N2 (ipsilateral) and N3 (contralateral) mediastinal LN involvement (1983, 1986). The last map (1997 regional LN classification) was recently replaced by a descriptive classification in anatomical zones. This new LN map of the TNM classification for lung cancer is a step toward using anatomical view points which might be the best way to better understand lung cancer lymphatic spread. Nowadays, the LNs are easily identified by current radiological imaging, and their resectability may be anticipated. Each LN chain may be removed by en-bloc lymphadenectomy performed during radical lung resection, a safe procedure which seems to be more oncological based than sampling, and which avoids the source of discrepancies pointed out during the labeling of LN stations by surgeons.

Entities:  

Mesh:

Year:  2010        PMID: 20573650     DOI: 10.1510/icvts.2010.236349

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  6 in total

1.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

2.  Prognostic significance of 4R lymph node dissection in patients with right primary non-small cell lung cancer.

Authors:  Di Zhou; Dongsheng Yue; Zhenfa Zhang; Pengfei Tian; Yingnan Feng; Zuo Liu; Bin Zhang; Meng Wang; Xiaoliang Zhao; Changli Wang
Journal:  World J Surg Oncol       Date:  2022-07-01       Impact factor: 3.253

3.  Prognostic analysis of the bronchoplastic and broncho-arterioplastic lobectomy of non-small cell lung cancers-10-year experiences of 161 patients.

Authors:  Li-Lan Zhao; Fang-Yu Zhou; Chen-Yang Dai; Yi-Jiu Ren; Ge-Ning Jiang; Ke Fei; Chang Chen
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

4.  Prognostic role of station 3A mediastinal nodes for non-small-cell lung cancers.

Authors:  Hui Zheng; Wen Gao; Ke Fei; Hui-Kang Xie; Ge-Ning Jiang; Jia-An Ding; Chao Li; Chang Chen; Lei Zhang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-06-19

5.  Risk factors of lobar lymph node metastases in non-primary tumor-bearing lobes among the patients of non-small-cell lung cancer.

Authors:  Jingwei Liu; Jian Li; Gang Lin; Zhiqiang Long; Qian Li; Bing Liu
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

6.  Effect of 3A lymph node resection on survival in patients with right-sided NSCLC: a retrospective, multicentre, propensity-score matching study.

Authors:  Marcin M Cackowski; Marcin Zbytniewski; Grzegorz M Gryszko; Michał Dziedzic; Katarzyna Woźnica; Tadeusz M Orłowski; Dariusz A Dziedzic
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.